Do analysts prefer LITS or GNLX?

Genelux has a consensus target price of $18.00, suggesting a potential upside of 510.58%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, LITS or GNLX?

Lite Strategy has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lite Strategy $65.30M 0.50 -$15.94M -$1.60 N/A Genelux $8K 16,523.54 -$32.15M -$0.85 N/A

Is LITS or GNLX more profitable?

Lite Strategy's return on equity of -90.81% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% Genelux N/A -174.55% -123.65%

Does the media favor LITS or GNLX?

In the previous week, Lite Strategy and Lite Strategy both had 1 articles in the media. Lite Strategy's average media sentiment score of 0.13 beat Genelux's score of 0.00 indicating that Lite Strategy is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lite Strategy 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NRXP or LITS?

NRx Pharmaceuticals presently has a consensus price target of $38.25, indicating a potential upside of 1,179.26%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NRXP or LITS more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Lite Strategy N/A -90.81% -89.33%

Do analysts recommend LITS or IFRX?

InflaRx has a consensus target price of $7.00, indicating a potential upside of 294.37%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InflaRx 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88

Which has preferable valuation & earnings, LITS or IFRX?

Lite Strategy has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lite Strategy $65.30M 0.50 -$15.94M -$1.60 N/A InflaRx $30K 4,277.16 -$51.63M -$0.71 N/A

Is LITS or IFRX more profitable?

InflaRx's return on equity of -88.30% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% InflaRx N/A -88.30% -65.77%

Does the media prefer LITS or IFRX?

In the previous week, InflaRx had 5 more articles in the media than Lite Strategy. MarketBeat recorded 6 mentions for InflaRx and 1 mentions for Lite Strategy. InflaRx's average media sentiment score of 0.45 beat Lite Strategy's score of 0.13 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lite Strategy 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LITS or VTVT?

vTv Therapeutics has a consensus price target of $56.67, suggesting a potential upside of 73.22%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is LITS or VTVT more profitable?

vTv Therapeutics' return on equity of 3.96% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% vTv Therapeutics N/A 3.96% 2.86%

Does the media prefer LITS or VTVT?

In the previous week, vTv Therapeutics had 3 more articles in the media than Lite Strategy. MarketBeat recorded 4 mentions for vTv Therapeutics and 1 mentions for Lite Strategy. vTv Therapeutics' average media sentiment score of 0.22 beat Lite Strategy's score of 0.13 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lite Strategy 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ENGN or LITS?

enGene currently has a consensus price target of $11.05, indicating a potential upside of 511.94%. Given enGene's stronger consensus rating and higher possible upside, research analysts clearly believe enGene is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 2 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.14 Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ENGN or LITS?

Lite Strategy has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Lite Strategy $65.30M 0.50 -$15.94M -$1.60 N/A

Is ENGN or LITS more profitable?

enGene's return on equity of -56.06% beat Lite Strategy's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Lite Strategy N/A -90.81% -89.33%

Does the media favor ENGN or LITS?

In the previous week, enGene had 10 more articles in the media than Lite Strategy. MarketBeat recorded 11 mentions for enGene and 1 mentions for Lite Strategy. enGene's average media sentiment score of 0.25 beat Lite Strategy's score of 0.13 indicating that enGene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lite Strategy 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lite Strategy (LITS) Competitors

$0.96 -0.03 (-2.67%)

As of 12:57 PM Eastern

Compare

LITS vs. GNLX, NRXP, IFRX, VTVT, and ENGN

Should you buy Lite Strategy stock or one of its competitors? MarketBeat compares Lite Strategy with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lite Strategy include Genelux (GNLX), NRx Pharmaceuticals (NRXP), InflaRx (IFRX), vTv Therapeutics (VTVT), and enGene (ENGN).

How does Lite Strategy compare to Genelux?

Lite Strategy (NASDAQ:LITS) and Genelux (NASDAQ:GNLX) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Lite Strategy has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.50	-$15.94M	-$1.60	N/A
Genelux	$8K	16,523.54	-$32.15M	-$0.85	N/A

In the previous week, Lite Strategy and Lite Strategy both had 1 articles in the media. Lite Strategy's average media sentiment score of 0.13 beat Genelux's score of 0.00 indicating that Lite Strategy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lite Strategy	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genelux has a consensus target price of $18.00, suggesting a potential upside of 510.58%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lite Strategy's return on equity of -90.81% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
Genelux	N/A	-174.55%	-123.65%

Lite Strategy has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Genelux has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 1.6% of Lite Strategy shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Lite Strategy and Genelux tied by winning 7 of the 14 factors compared between the two stocks.

How does Lite Strategy compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Lite Strategy (NASDAQ:LITS) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

NRx Pharmaceuticals presently has a consensus price target of $38.25, indicating a potential upside of 1,179.26%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NRx Pharmaceuticals has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

In the previous week, Lite Strategy had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 1 mentions for Lite Strategy and 0 mentions for NRx Pharmaceuticals. Lite Strategy's average media sentiment score of 0.13 beat NRx Pharmaceuticals' score of 0.00 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Lite Strategy	Neutral

NRx Pharmaceuticals' return on equity of 0.00% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Lite Strategy	N/A	-90.81%	-89.33%

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 52.4% of Lite Strategy shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Lite Strategy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lite Strategy has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	88.07	-$28.62M	-$1.09	N/A
Lite Strategy	$65.30M	0.50	-$15.94M	-$1.60	N/A

Summary

NRx Pharmaceuticals beats Lite Strategy on 8 of the 15 factors compared between the two stocks.

How does Lite Strategy compare to InflaRx?

Lite Strategy (NASDAQ:LITS) and InflaRx (NASDAQ:IFRX) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

InflaRx has a consensus target price of $7.00, indicating a potential upside of 294.37%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

InflaRx's return on equity of -88.30% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
InflaRx	N/A	-88.30%	-65.77%

Lite Strategy has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.50	-$15.94M	-$1.60	N/A
InflaRx	$30K	4,277.16	-$51.63M	-$0.71	N/A

Lite Strategy has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market.

52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 1.6% of Lite Strategy shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, InflaRx had 5 more articles in the media than Lite Strategy. MarketBeat recorded 6 mentions for InflaRx and 1 mentions for Lite Strategy. InflaRx's average media sentiment score of 0.45 beat Lite Strategy's score of 0.13 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lite Strategy	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InflaRx beats Lite Strategy on 12 of the 16 factors compared between the two stocks.

How does Lite Strategy compare to vTv Therapeutics?

Lite Strategy (NASDAQ:LITS) and vTv Therapeutics (NASDAQ:VTVT) are related small-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

vTv Therapeutics' return on equity of 3.96% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
vTv Therapeutics	N/A	3.96%	2.86%

Lite Strategy has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, vTv Therapeutics had 3 more articles in the media than Lite Strategy. MarketBeat recorded 4 mentions for vTv Therapeutics and 1 mentions for Lite Strategy. vTv Therapeutics' average media sentiment score of 0.22 beat Lite Strategy's score of 0.13 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lite Strategy	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lite Strategy has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.50	-$15.94M	-$1.60	N/A
vTv Therapeutics	$1.02M	126.37	-$26.97M	-$0.93	N/A

vTv Therapeutics has a consensus price target of $56.67, suggesting a potential upside of 73.22%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

vTv Therapeutics beats Lite Strategy on 11 of the 15 factors compared between the two stocks.

How does Lite Strategy compare to enGene?

enGene (NASDAQ:ENGN) and Lite Strategy (NASDAQ:LITS) are related small-cap companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Lite Strategy has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Lite Strategy	$65.30M	0.50	-$15.94M	-$1.60	N/A

In the previous week, enGene had 10 more articles in the media than Lite Strategy. MarketBeat recorded 11 mentions for enGene and 1 mentions for Lite Strategy. enGene's average media sentiment score of 0.25 beat Lite Strategy's score of 0.13 indicating that enGene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lite Strategy	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.2% of enGene shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 1.6% of Lite Strategy shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

enGene currently has a consensus price target of $11.05, indicating a potential upside of 511.94%. Given enGene's stronger consensus rating and higher possible upside, research analysts clearly believe enGene is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

enGene's return on equity of -56.06% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Lite Strategy	N/A	-90.81%	-89.33%

Summary

enGene beats Lite Strategy on 9 of the 14 factors compared between the two stocks.

Get Lite Strategy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LITS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LITS vs. The Competition

Export

Metric	Lite Strategy	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$32.50M	$27.26B	$14.06B	$12.94B
Dividend Yield	N/A	5.79%	5.95%	10.03%
P/E Ratio	-0.60	20.10	28.83	25.45
Price / Sales	0.50	392.52	458.84	115.11
Price / Cash	N/A	43.87	29.95	34.82
Price / Book	N/A	3.21	3.74	6.33
Net Income	-$15.94M	$1.09B	$1.31B	$347.60M
7 Day Performance	-1.55%	0.71%	0.88%	2.78%
1 Month Performance	0.48%	2.90%	1.24%	-2.36%
1 Year Performance	N/A	-8.97%	13.76%	20.74%

Lite Strategy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LITS Lite Strategy	1.1888 of 5 stars	$0.96 -2.7%	N/A	N/A	$32.50M	$65.30M	N/A	100
GNLX Genelux	1.4838 of 5 stars	$2.94 +1.7%	$18.00 +512.2%	-15.1%	$131.83M	$10K	N/A	10	Positive News Upcoming Earnings Gap Up
NRXP NRx Pharmaceuticals	1.5733 of 5 stars	$3.63 -3.3%	$38.25 +955.2%	+25.1%	$131.52M	$1.23M	N/A	2
IFRX InflaRx	2.8069 of 5 stars	$1.73 -0.9%	$7.00 +305.8%	+103.5%	$124.70M	$30K	N/A	60	Upcoming Earnings Gap Up
VTVT vTv Therapeutics	2.6903 of 5 stars	$30.95 +0.7%	$56.67 +83.1%	+122.0%	$121.92M	$1.02M	N/A	9	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LITS) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lite Strategy (LITS) Competitors

LITS vs. GNLX, NRXP, IFRX, VTVT, and ENGN

How does Lite Strategy compare to Genelux?

Summary

How does Lite Strategy compare to NRx Pharmaceuticals?

Summary

How does Lite Strategy compare to InflaRx?

Summary

How does Lite Strategy compare to vTv Therapeutics?

Summary

How does Lite Strategy compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS vs. The Competition

Lite Strategy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lite Strategy (LITS) Competitors

LITS vs. GNLX, NRXP, IFRX, VTVT, and ENGN

How does Lite Strategy compare to Genelux?

Which has stronger valuation and earnings, LITS or GNLX?

Does the media favor LITS or GNLX?

Do analysts prefer LITS or GNLX?

Is LITS or GNLX more profitable?

Which has more volatility and risk, LITS or GNLX?

Do institutionals and insiders have more ownership in LITS or GNLX?

Summary

How does Lite Strategy compare to NRx Pharmaceuticals?

Do analysts recommend NRXP or LITS?

Which has more risk & volatility, NRXP or LITS?

Does the media refer more to NRXP or LITS?

Is NRXP or LITS more profitable?

Do institutionals and insiders believe in NRXP or LITS?

Which has preferable earnings and valuation, NRXP or LITS?

Summary

How does Lite Strategy compare to InflaRx?

Do analysts recommend LITS or IFRX?

Is LITS or IFRX more profitable?

Which has preferable valuation & earnings, LITS or IFRX?

Which has more risk & volatility, LITS or IFRX?

Do institutionals and insiders believe in LITS or IFRX?

Does the media prefer LITS or IFRX?

Summary

How does Lite Strategy compare to vTv Therapeutics?

Is LITS or VTVT more profitable?

Which has more volatility and risk, LITS or VTVT?

Does the media prefer LITS or VTVT?

Which has better earnings and valuation, LITS or VTVT?

Do analysts prefer LITS or VTVT?

Do institutionals and insiders hold more shares of LITS or VTVT?

Summary

How does Lite Strategy compare to enGene?

Which has higher valuation & earnings, ENGN or LITS?

Does the media favor ENGN or LITS?

Do insiders & institutionals have more ownership in ENGN or LITS?

Do analysts prefer ENGN or LITS?

Which has more risk and volatility, ENGN or LITS?

Is ENGN or LITS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS vs. The Competition

Lite Strategy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools